Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 21

1.

Flucelvax Tetra: a surface antigen, inactivated, influenza vaccine prepared in cell cultures.

Bühler S, Ramharter M.

ESMO Open. 2019 Jan 21;4(1):e000481. doi: 10.1136/esmoopen-2018-000481. eCollection 2019. No abstract available.

2.

[The immunosuppressed traveler : vaccination guidelines].

Eperon G, Bühler S, Enriquez N, Vaudaux B.

Rev Med Suisse. 2018 May 2;14(605):922-933. French.

PMID:
29722498
3.

Safety of live vaccines on immunosuppressive or immunomodulatory therapy-a retrospective study in three Swiss Travel Clinics.

Huber F, Ehrensperger B, Hatz C, Chappuis F, Bühler S, Eperon G.

J Travel Med. 2018 Jan 1;25(1). doi: 10.1093/jtm/tax082.

PMID:
29394383
4.

Stop measles in Switzerland - The importance of travel medicine.

Bühler S, Lang P, Bally B, Hatz C, Jaeger VK.

Vaccine. 2017 Jun 27;35(30):3760-3763. doi: 10.1016/j.vaccine.2017.05.042. Epub 2017 May 29.

5.
6.

Single-Dose Hepatitis A Immunization: 7.5-Year Observational Pilot Study in Nicaraguan Children to Assess Protective Effectiveness and Humoral Immune Memory Response.

Mayorga O, Bühler S, Jaeger VK, Bally S, Hatz C, Frösner G, Protzer U, Van Damme P, Egger M, Herzog C.

J Infect Dis. 2016 Nov 15;214(10):1498-1506. Epub 2016 Sep 6.

PMID:
27601623
7.

Varicella seroprevalence in individuals with a negative or unknown varicella history - results from a large travel clinic in Switzerland between 2008 and 2015.

Freuler M, De Crom S, Hatz C, Bühler S.

Swiss Med Wkly. 2016 Sep 1;146:w14342. doi: 10.4414/smw.2016.14342. eCollection 2016.

8.

Unpredictable checks of yellow fever vaccination certificates upon arrival in Tanzania.

Schönenberger S, Hatz C, Bühler S.

J Travel Med. 2016 Jun 13;23(5). doi: 10.1093/jtm/taw035. Print 2016 May.

PMID:
27296582
9.

[Vaccinations in patients with autoimmune diseases].

Bühler S, Hatz C.

Ther Umsch. 2016;73(5):275-80. doi: 10.1024/0040-5930/a000792. Review. German.

PMID:
27268452
10.

One-year immunogenicity kinetics and safety of a purified chick embryo cell rabies vaccine and an inactivated Vero cell-derived Japanese encephalitis vaccine administered concomitantly according to a new, 1-week, accelerated primary series.

Cramer JP, Jelinek T, Paulke-Korinek M, Reisinger EC, Dieckmann S, Alberer M, Bühler S, Bosse D, Meyer S, Fragapane E, Costantini M, Pellegrini M, Lattanzi M, Dovali C.

J Travel Med. 2016 Mar 19;23(3). pii: taw011. doi: 10.1093/jtm/taw011. Print 2016 Mar.

PMID:
26994987
11.

The elderly, the young and the pregnant traveler -- A retrospective data analysis from a large Swiss Travel Center with a special focus on malaria prophylaxis and yellow fever vaccination.

Jaeger VK, Tschudi N, Rüegg R, Hatz C, Bühler S.

Travel Med Infect Dis. 2015 Nov-Dec;13(6):475-84. doi: 10.1016/j.tmaid.2015.10.001. Epub 2015 Oct 16.

PMID:
26526774
12.

Vaccination recommendations for adult patients with autoimmune inflammatory rheumatic diseases.

Bühler S, Eperon G, Ribi C, Kyburz D, van Gompel F, Visser LG, Siegrist CA, Hatz C.

Swiss Med Wkly. 2015 Jul 28;145:w14159. doi: 10.4414/smw.2015.14159. eCollection 2015.

13.

Short-Term Immunogenicity and Safety of an Accelerated Pre-Exposure Prophylaxis Regimen With Japanese Encephalitis Vaccine in Combination With a Rabies Vaccine: A Phase III, Multicenter, Observer-Blind Study.

Jelinek T, Burchard GD, Dieckmann S, Bühler S, Paulke-Korinek M, Nothdurft HD, Reisinger E, Ahmed K, Bosse D, Meyer S, Costantini M, Pellegrini M.

J Travel Med. 2015 Jul-Aug;22(4):225-31. doi: 10.1111/jtm.12210. Epub 2015 May 22.

14.

To vaccinate or let it be--current recommendations and the reality about yellow fever vaccination.

Bühler S, Jaeger VK, Kling K, Hatz C.

Swiss Med Wkly. 2014 Dec 23;144:w14095. doi: 10.4414/smw.2014.14095. eCollection 2014. No abstract available.

15.

Travelers with immune-mediated inflammatory diseases: are they different?

Jaeger VK, Rüegg R, Steffen R, Hatz C, Bühler S.

J Travel Med. 2015 May-Jun;22(3):161-7. doi: 10.1111/jtm.12184. Epub 2014 Dec 22.

16.

A profile of travelers--an analysis from a large swiss travel clinic.

Bühler S, Rüegg R, Steffen R, Hatz C, Jaeger VK.

J Travel Med. 2014 Sep-Oct;21(5):324-31. doi: 10.1111/jtm.12139. Epub 2014 Jun 17.

17.

Hepatitis A vaccination in patients with rheumatic diseases and drug-induced immunosuppression.

Bühler S, Visser LG.

Travel Med Infect Dis. 2014 Mar-Apr;12(2):115-7. doi: 10.1016/j.tmaid.2014.02.003. Epub 2014 Feb 28. No abstract available.

PMID:
24629802
18.
19.

Control of M184V HIV-1 mutants by CD8 T-cell responses.

Vollbrecht T, Eberle J, Roider J, Bühler S, Stirner R, Henrich N, Seybold U, Bogner JR, Draenert R.

Med Microbiol Immunol. 2012 May;201(2):201-11. doi: 10.1007/s00430-011-0222-1. Epub 2011 Dec 27.

PMID:
22200907
20.

Neutralization assay using a modified vaccinia virus Ankara vector expressing the green fluorescent protein is a high-throughput method to monitor the humoral immune response against vaccinia virus.

Cosma A, Bühler S, Nagaraj R, Staib C, Hammarin AL, Wahren B, Goebel FD, Erfle V, Sutter G.

Clin Diagn Lab Immunol. 2004 Mar;11(2):406-10.

Supplemental Content

Loading ...
Support Center